Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer
-
Published:2020-12-29
Issue:2
Volume:54
Page:156-165
-
ISSN:1860-1480
-
Container-title:Medical Molecular Morphology
-
language:en
-
Short-container-title:Med Mol Morphol
Author:
Rico Sebastian Dwertmann, Höflmayer Doris, Büscheck Franziska, Dum David, Luebke Andreas M., Kluth Martina, Hube-Magg Claudia, Hinsch Andrea, Möller-Koop Christina, Perez Daniel, Izbicki Jakob R., Neipp Michael, Mofid Hamid, Lárusson Hannes, Daniels Thies, Isbert Christoph, Coerper Stephan, Ditterich Daniel, Rupprecht Holger, Goetz Albert, Fraune Christoph, Möller Katharina, Menz Anne, Bernreuther Christian, Clauditz Till S., Sauter Guido, Uhlig Ria, Wilczak Waldemar, Simon RonaldORCID, Steurer Stefan, Lebok Patrick, Burandt Eike, Krech Till, Marx Andreas H.
Abstract
AbstractMucin 5AC (MUC5AC) is a secreted gel-forming mucin expressed by several epithelia. In the colon, MUC5AC is expressed in scattered normal epithelial cells but can be abundant in colorectal cancers. To clarify the relationship of MUC5AC expression with parameters of tumor aggressiveness and mismatch repair deficiency (dMMR) in colorectal cancer, a tissue microarray containing 1812 colorectal cancers was analyzed by immunohistochemistry. MUC5AC expression was found in 261 (15.7%) of 1,667 analyzable colorectal cancers. MUC5AC expression strongly depended on the tumor location and gradually decreased from proximal (27.4% of cecum cancers) to distal (10.6% of rectal cancers; p < 0.0001). MUC5AC expression was also strongly linked to dMMR. dMMR was found in 21.3% of 169 cancers with MUC5AC positivity but in only 4.6% of 1051 cancers without detectable MUC5AC expression (p < 0.0001). A multivariate analysis showed that dMMR status and tumor localization predicted MUC5AC expression independently (p < 0.0001 each). MUC5AC expression was unrelated to pT and pN status. This also applied to the subgroups of 1136 proficient MMR (pMMR) and of 84 dMMR cancers. The results of our study show a strong association of MUC5AC expression with proximal and dMMR colorectal cancers. However, MUC5AC expression is unrelated to colon cancer aggressiveness.
Publisher
Springer Science and Business Media LLC
Subject
Molecular Biology,General Medicine,Pathology and Forensic Medicine
Reference48 articles.
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424 2. Afrasanie VA, Marinca MV, Alexa-Stratulat T et al (2019) KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer—practical implications for the clinician. Radiol Oncol 53:265–274 3. Sahin IH, Akce M, Alese O et al (2019) Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms. Br J Cancer 121:809–818 4. Amin MB, Edge S, Greene F et al (2017) AJCC Cancer Staging Manual. Springer, New York 5. Fleming M, Ravula S, Tatishchev SF, Wang HL (2012) Colorectal carcinoma: pathologic aspects. J Gastrointest Oncol 3:153–173
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|